INIS
adipose tissue
6%
adjustments
9%
adolescents
5%
adults
37%
arteries
14%
assessments
9%
biological markers
12%
blood
8%
blood pressure
8%
bones
5%
brain
13%
cancer
7%
carcinomas
11%
cardiovascular diseases
12%
children
6%
cholesterol
8%
clinical trials
5%
comparative evaluations
35%
concentration
8%
control
26%
data
36%
density
5%
design
13%
diabetes mellitus
27%
diet
6%
diseases
59%
education
7%
evaluation
6%
exercise
5%
fasting
6%
fats
8%
fibers
5%
fructose
10%
genes
9%
genetics
8%
glucose
61%
guidelines
15%
hazards
5%
healing
7%
hormones
9%
humans
12%
incidents
7%
inflammation
13%
insulin
39%
intake
10%
interventions
13%
kidneys
8%
levels
38%
lipids
15%
liver
23%
losses
6%
management
18%
men
19%
metabolism
29%
metabolites
6%
monitoring
10%
mortality
7%
muscles
11%
nerves
7%
netherlands
6%
obesity
8%
oxidation
5%
pancreas
8%
patients
93%
people
46%
peptides
5%
performance
12%
plasma
17%
populations
29%
prediction
7%
proteins
10%
quality of life
21%
range
10%
receptors
7%
recommendations
6%
regression analysis
8%
reviews
28%
risks
57%
screening
5%
sensitivity
17%
sensors
6%
sex
20%
skin
9%
sleep
5%
stiffness
8%
surgery
5%
surveys
5%
symptoms
17%
therapy
9%
thickness
7%
thyroid
13%
tolerance
9%
triglycerides
5%
tumors
10%
ulcers
16%
validation
5%
values
9%
volume
7%
women
16%
wounds
5%
Keyphrases
Advanced Glycation End Products
5%
Arterial Stiffness
6%
Body Mass Index
5%
Cardiovascular Disease
8%
Cardiovascular Risk
8%
Cognitive Performance
6%
Confidence Interval
13%
Continuous Glucose Monitoring
6%
Depressive Symptoms
8%
Diabetes
25%
Diabetic Foot
19%
Diabetic Foot Ulcer
9%
Dutch
15%
Endothelial Dysfunction
5%
Foot Ulcer
8%
Fructose
7%
Glucose Metabolism Status
5%
Glucose Variability
5%
Glycemic Control
7%
Health-related Quality of Life
6%
Healthcare Professionals
5%
Hemoglobin A1c (HbA1c)
12%
Hepatic Fat
9%
Hyperglycemia
5%
Hypo
6%
Hypoglycemia
30%
Hypoglycemia Unawareness
6%
Insulin
7%
Insulin Resistance
7%
Insulin Sensitivity
13%
International Working Groups
12%
Maastricht
100%
Metformin
5%
Microvascular Dysfunction
5%
Multiple Endocrine Neoplasia Type 1 (MEN1)
13%
Netherlands
6%
Non-alcoholic Fatty Liver Disease (NAFLD)
10%
Non-associated
6%
Normal Glucose Tolerance
10%
Odds Ratio
6%
Oral Glucose Tolerance Test
5%
Patients with Diabetes
19%
Peripheral Arterial Disease
13%
Phenylketonuria
5%
Physical Activity
11%
Placebo
5%
Population-based Cohort Study
8%
Pre-diabetes (pre-DM)
21%
Quality of Life
11%
Randomized Controlled Trial
8%
Risk Factors
6%
Sedentary Behavior
6%
Sex Hormone-binding Globulin
5%
Skeletal muscle
6%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
5%
Survivors
5%
Type 1 Diabetes Mellitus (T1DM)
30%
Type 2 Diabetes Mellitus (T2DM)
84%
Type 2 Diabetic Patients
13%
Type I Diabetes
23%
Without Diabetes
5%
Medicine and Dentistry
Amputation
5%
Arterial Stiffness
9%
Arteriosclerosis Obliterans
12%
Awareness
7%
Biological Marker
10%
Body Mass Index
6%
Cardiovascular Disease
11%
Cardiovascular System
6%
Cohort Analysis
8%
Depression
8%
Diabetes
38%
Diabetes Mellitus
11%
Diabetic Foot Ulcer
5%
Diabetic Neuropathy
6%
Differentiated Thyroid Cancer
8%
Disease
9%
Endothelial Dysfunction
6%
Foot Disease
6%
Foot Ulcer
7%
Fructose
5%
Glucose Metabolism
13%
Glycemic Control
5%
Hemoglobin A1c
5%
Hypoglycemia
19%
Impaired Glucose Tolerance
20%
Insulin Dependent Diabetes Mellitus
16%
Insulin Sensitivity
7%
Maturity Onset Diabetes of the Young
60%
Multiple Endocrine Neoplasia Type I
11%
Nonalcoholic Fatty Liver
5%
Oral Glucose Tolerance Test
5%
Patient with Type 2 Diabetes
5%
Physical Activity
12%
Prevalence
6%
Quality of Life
14%
Randomized Controlled Trial
5%
Skeletal Muscle
5%
Systematic Review
17%